Completed EARLY_PHASE1 INTERVENTIONAL 3-arm NCT01174056

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone

Sponsor: Doris Duke Charitable Foundation

Interventions Pioglitazone Pioglitazone placebo Zileuton Zileuton placebo

Updated 7 times since 2017 Last updated: Apr 22, 2014 Started: Jul 31, 2011 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Lung Inflammation and is currently completed. Doris Duke Charitable Foundation leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed EARLY_PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Doris Duke Charitable Foundation
Washington University School of Medicine

Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St Louis, United States